Top

Endocrine

Published in:

01-01-2019 | Meta-Analysis

Effectiveness and safety of pegvisomant: a systematic review and meta-analysis of observational longitudinal studies

Authors: Letícia P. Leonart, Fernanda S. Tonin, Vinicius L. Ferreira, Fernando Fernandez-Llimos, Roberto Pontarolo

Published in: Endocrine | Issue 1/2019

Abstract

Purpose

Acromegaly is a rare disease that often requires drug treatment to achieve control, with pegvisomant being one of the most widely used therapies. In the present paper, we aimed to obtain evidence regarding the effectiveness and safety of pegvisomant by reviewing real-world observational longitudinal studies.

Methods

A systematic review was performed with a meta-analysis of event rates (95% confidence interval (CI)) using a random effects model. Sensitivity and subgroup analyses were performed (comprehensive meta-analysis 2.0). The systematic review was performed in accordance to preferred reporting items for systematic reviews and meta-analyses, meta-analysis of observational studies in epidemiology, and Cochrane recommendations (PROSPERO register CRD 42017059880). PubMed, Scopus, Web of Science, and SciELO were used to search for literature. Observational studies in patients using pegvisomant for the treatment of acromegaly were included.

Results

Initially, 552 papers were retrieved from the databases; and 31 articles were included in the qualitative analysis and 14 in the quantitative analysis. Eight primary meta-analyses were performed. The overall rate of patients with disease control was of 60.9% (51.8–69.3%; 95% CI). When considering patients under monotherapy, the control rate was 71.7% (64.0–78.4%; 95% CI). Tumor growth was estimated in 7.3% (4.7–11.1%; 95% CI) and elevation of transaminases in 3.0% (1.7–5.2%; 95% CI).

Conclusions

The real-world data showed that the effectiveness of pegvisomant is not as high as reported in interventional studies. Acromegaly appears to be better controlled when pegvisomant is used as a monotherapy. No serious adverse events were associated with the use of pegvisomant; however, given the high cost of this drug, further studies are required.

Available only for authorised users

K. Gunawardane, T. Krarup Hansen, J. Sandahl Christiansen, J.O. Lunde Jorgensen, Normal physiology of growth hormone in adults. in L.J. De Groot, G. Chrousos, K. Dungan, K.R. Feingold, A. Grossman, J.M. Hershman, C. Koch, M. Korbonits, R. McLachlan, M. New, J. Purnell, R. Rebar, F. Singer, A. Vinik (eds.) Endotext. (South Dartmouth, MA, 2000)

L. Katznelson, E.R. Laws Jr., S. Melmed, M.E. Molitch, M.H. Murad, A. Utz, J.A. Wass, S. Endocrine, Acromegaly: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99(11), 3933–3951 (2014). https://doi.org/10.1210/jc.2014-2700 CrossRefPubMed

A. Colao, D. Ferone, P. Marzullo, G. Lombardi, Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr. Rev. 25(1), 102–152 (2004). https://doi.org/10.1210/er.2002-0022 CrossRefPubMed

S. Melmed, Acromegaly pathogenesis and treatment. J. Clin. Invest 119(11), 3189–3202 (2009). https://doi.org/10.1172/JCI39375 CrossRefPubMedPubMedCentral

P. Chanson, S. Salenave, P. Kamenicky, Acromegaly. Handb. Clin. Neurol. 124, 197–219 (2014). https://doi.org/10.1016/B978-0-444-59602-4.00014-9 CrossRefPubMed

S. Stormann, J. Schopohl, Perspectives on investigational drugs for acromegaly. Expert Opin. Investig. Drugs 25(4), 381–384 (2016). https://doi.org/10.1517/13543784.2016.1142530 CrossRefPubMed

J.M. Silverstein, Need for improved monitoring in patients with acromegaly. Endocr. Connect 4(4), R59–67 (2015). https://doi.org/10.1530/EC-15-0064 CrossRefPubMedPubMedCentral

S.J. Neggers, A. Muhammad, A.J. van der Lely, Pegvisomant treatment in acromegaly. Neuroendocrinology 103(1), 59–65 (2016). https://doi.org/10.1159/000381644 CrossRefPubMed

FDA: Pegvisomant Approval (2018), https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process. Accessed 19 July 2018

10.

EMA: Pegvisomant Approval (2018).

11.

D.J. Moore, Y. Adi, M.J. Connock, S. Bayliss, Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation. BMC Endocr. Disord. 9, 20 (2009). https://doi.org/10.1186/1472-6823-9-20 CrossRefPubMedPubMedCentral

12.

L.P. Leonart, V.L. Ferreira, F.S. Tonin, F. Fernandez-Llimos, R. Pontarolo, Medical treatments for acromegaly: a systematic review and network meta-analysis. Value Health 21(7), 874–880 (2018). https://doi.org/10.1016/j.jval.2017.12.014 CrossRefPubMed

13.

P.J. Trainer, W.M. Drake, L. Katznelson, P.U. Freda, V. Herman-Bonert, A.J. van der Lely, E.V. Dimaraki, P.M. Stewart, K.E. Friend, M.L. Vance, G.M. Besser, J.A. Scarlett, M.O. Thorner, C. Parkinson, A. Klibanski, J.S. Powell, A.L. Barkan, M.C. Sheppard, M. Malsonado, D.R. Rose, D.R. Clemmons, G. Johannsson, B.A. Bengtsson, S. Stavrou, D.L. Kleinberg, D.M. Cook, L.S. Phillips, M. Bidlingmaier, C.J. Strasburger, S. Hackett, K. Zib, W.F. Bennett, R.J. Davis, Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N. Engl. J. Med 342(16), 1171–1177 (2000). https://doi.org/10.1056/NEJM200004203421604 CrossRefPubMed

14.

A.J. van der Lely, R.K. Hutson, P.J. Trainer, G.M. Besser, A.L. Barkan, L. Katznelson, A. Klibanski, V. Herman-Bonert, S. Melmed, M.L. Vance, P.U. Freda, P.M. Stewart, K.E. Friend, D.R. Clemmons, G. Johannsson, S. Stavrou, D.M. Cook, L.S. Phillips, C.J. Strasburger, S. Hackett, K.A. Zib, R.J. Davis, J.A. Scarlett, M.O. Thorner, Long-term treatment of acromegaly with pegvisomant, a growth hormone-receptor antagonist. Lancet 358(9295), 1754–1759 (2001)CrossRef

15.

S. de Lusignan, L. Crawford, N. Munro, Creating and using real-world evidence to answer questions about clinical effectiveness. J. Innov. Health Inform. 22(3), 368–373 (2015). https://doi.org/10.14236/jhi.v22i3.177 CrossRefPubMed

16.

M.L. Berger, H. Sox, R.J. Willke, D.L. Brixner, H.G. Eichler, W. Goettsch, D. Madigan, A. Makady, S. Schneeweiss, R. Tarricone, S.V. Wang, J. Watkins, C. Daniel Mullins, Good practices for real-world data studies of treatment and/or comparative effectiveness: recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in healthcare decision making. Pharmacoepidemiol. Drug Saf. 26(9), 1033–1039 (2017). https://doi.org/10.1002/pds.4297 CrossRefPubMedPubMedCentral

17.

J.P.T. Higgins, G.S.: Cochrane handbook for systematic reviews of interventions, version 5.1.0. The Cochrane Collaboration (2011).

18.

A. Liberati, D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. Gotzsche, J.P. Ioannidis, M. Clarke, P.J. Devereaux, J. Kleijnen, D. Moher, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Br Med J 339, b2700 (2009). https://doi.org/10.1136/bmj.b2700 CrossRef

19.

D.F. Stroup, J.A. Berlin, S.C. Morton, I. Olkin, G.D. Williamson, D. Rennie, D. Moher, B.J. Becker, T.A. Sipe, S.B. Thacker, Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. J Am Med Assoc 283(15), 2008–2012 (2000)CrossRef

20.

G.A. Wells, B. Shea, D. O’Connell, J. Peterson, V. Welch, M. Losos, P. Tugwell, The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Accessed 13 June 2018

21.

T. Brue, ACROSTUDY: status update on 469 patients. Horm. Res. 71(Suppl 1), S34–S38 (2009). https://doi.org/10.1159/000178035 CrossRef

22.

P.J. Trainer, ACROSTUDY: the first 5 years. Eur. J. Endocrinol. 161(Suppl 1), S19–S24 (2009). https://doi.org/10.1530/EJE-09-0322 CrossRefPubMed

23.

A.J. van der Lely, B.M. Biller, T. Brue, M. Buchfelder, E. Ghigo, R. Gomez, J. Hey-Hadavi, F. Lundgren, N. Rajicic, C.J. Strasburger, S.M. Webb, M. Koltowska-Haggstrom, Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J. Clin. Endocrinol. Metab. 97(5), 1589–1597 (2012). https://doi.org/10.1210/jc.2011-2508 CrossRefPubMed

24.

P.U. Freda, M.B. Gordon, N. Kelepouris, P. Jonsson, M. Koltowska-Haggstrom, A.J. van der Lely, Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY. Endocr. Pract. 21(3), 264–274 (2015). https://doi.org/10.4158/EP14330.OR CrossRefPubMedPubMedCentral

25.

N.A. Tritos, P. Chanson, C. Jimenez, D. King, P.J. Jonsson, A. Klibanski, B.M. Biller, Effectiveness of first-line pegvisomant monotherapy in acromegaly: an ACROSTUDY analysis. Eur. J. Endocrinol. 176(2), 213–220 (2017). https://doi.org/10.1530/EJE-16-0697 CrossRefPubMed

26.

C.J. Strasburger, A. Mattsson, P. Wilton, F. Aydin, J. Hey-Hadavi, B.M.K. Biller, Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant. Eur. J. Endocrinol. 178(4), 321–329 (2018). https://doi.org/10.1530/EJE-17-0996 CrossRefPubMedPubMedCentral

27.

I. Schreiber, M. Buchfelder, M. Droste, K. Forssmann, K. Mann, B. Saller, C.J. Strasburger, I. German Pegvisomant, Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur. J. Endocrinol. 156(1), 75–82 (2007). https://doi.org/10.1530/eje.1.02312 CrossRefPubMed

28.

C.J. Strasburger, M. Buchfelder, M. Droste, K. Mann, G.K. Stalla, B. Saller, I. German Pegvisomant, Experience from the German pegvisomant observational study. Horm. Res. 68(Suppl 5), S70–S73 (2007). https://doi.org/10.1159/000110481 CrossRef

29.

M. Buchfelder, S. Schlaffer, M. Droste, K. Mann, B. Saller, K. Brubach, G.K. Stalla, C.J. Strasburger; German Pegvisomant Observational Study, The German ACROSTUDY: past and present. Eur. J. Endocrinol. 161(Suppl 1), S3–S10 (2009). https://doi.org/10.1530/EJE-09-0350 CrossRefPubMed

30.

M. Buchfelder, D. Weigel, M. Droste, K. Mann, B. Saller, K. Brubach, G.K. Stalla, M. Bidlingmaier, C.J. Strasburger, Investigators of German Pegvisomant Observational Study. Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study. Eur. J. Endocrinol. 161(1), 27–35 (2009). https://doi.org/10.1530/EJE-08-0910 CrossRefPubMed

31.

C. Berg, S. Petersenn, H. Lahner, B.L. Herrmann, M. Buchfelder, M. Droste, G.K. Stalla, C.J. Strasburger, U. Roggenbuck, N. Lehmann, S. Moebus, K.H. Jockel, S. Mohlenkamp, R. Erbel, B. Saller, K. Mann; Investigative Group of the Heinz Nixdorf Recall Study and the German Pegvisomant Observational Study Board and Investigators, Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. J. Clin. Endocrinol. Metab. 95(8), 3648–3656 (2010). https://doi.org/10.1210/jc.2009-2570 CrossRefPubMed

32.

C. Urbani, C. Sardella, A. Calevro, G. Rossi, I. Scattina, M. Lombardi, I. Lupi, L. Manetti, E. Martino, F. Bogazzi, Effects of medical therapies for acromegaly on glucose metabolism. Eur. J. Endocrinol. 169(1), 99–108 (2013). https://doi.org/10.1530/EJE-13-0032 CrossRefPubMed

33.

A. Bianchi, F. Valentini, R. Iuorio, M. Poggi, R. Baldelli, M. Passeri, A. Giampietro, L. Tartaglione, S. Chiloiro, M. Appetecchia, P. Gargiulo, A. Fabbri, V. Toscano, A. Pontecorvi, L. De Marinis, Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes. J. Exp. Clin. Cancer Res 32, 40 (2013). https://doi.org/10.1186/1756-9966-32-40 CrossRefPubMedPubMedCentral

34.

S. Grottoli, P. Maffei, F. Bogazzi, S. Cannavo, A. Colao, E. Ghigo, R. Gomez, E. Graziano, M. Monterubbianesi, P. Jonsson, L. De Marinis, ACROSTUDY: the Italian experience. Endocrine 48(1), 334–341 (2015). https://doi.org/10.1007/s12020-014-0393-9 CrossRefPubMed

35.

S. Cannavo, F. Bogazzi, A. Colao, L. De Marinis, P. Maffei, R. Gomez, E. Graziano, M. Monterubbianesi, S. Grottoli, G. Italian Acrostudy, Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience. J. Endocrinol. Invest 38(10), 1099–1109 (2015). https://doi.org/10.1007/s40618-015-0289-4 CrossRefPubMed

36.

R.S. Auriemma, L.F. Grasso, M. Galdiero, M. Galderisi, C. Pivonello, C. Simeoli, M.C. De Martino, R. Ferrigno, M. Negri, C. de Angelis, R. Pivonello, A. Colao, Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. Endocrine 55(3), 872–884 (2017). https://doi.org/10.1007/s12020-016-0995-5 CrossRefPubMed

37.

M. Ragonese, S. Grottoli, P. Maffei, A. Alibrandi, M.R. Ambrosio, G. Arnaldi, A. Bianchi, S. Puglisi, M.C. Zatelli, L. De Marinis, E. Ghigo, A. Giustina, F. Maffezzoni, C. Martini, L. Trementino, S. Cannavo, How to improve effectiveness of pegvisomant treatment in acromegalic patients. J. Endocrinol. Invest. (2017). https://doi.org/10.1007/s40618-017-0773-0

38.

S. Chiloiro, G. Mazziotti, A. Giampietro, A. Bianchi, S. Frara, M. Mormando, A. Pontecorvi, A. Giustina, L. De Marinis, Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly. Pituitary (2018). https://doi.org/10.1007/s11102-018-0873-7

39.

M. Marazuela, T. Lucas, C. Alvarez-Escola, M. Puig-Domingo, N.G. de la Torre, P. de Miguel-Novoa, A. Duran-Hervada, R. Manzanares, M. Luque-Ramirez, I. Halperin, F.F. Casanueva, I. Bernabeu, Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy. Eur. J. Endocrinol. 160(4), 535–542 (2009). https://doi.org/10.1530/EJE-08-0705 CrossRefPubMed

40.

M. Marazuela, A.E. Paniagua, M.D. Gahete, T. Lucas, C. Alvarez-Escola, R. Manzanares, J. Cameselle-Teijeiro, M. Luque-Ramirez, R.M. Luque, E. Fernandez-Rodriguez, J.P. Castano, I. Bernabeu, Somatotroph tumor progression during pegvisomant therapy: a clinical and molecular study. J. Clin. Endocrinol. Metab. 96(2), E251–259 (2011). https://doi.org/10.1210/jc.2010-1742 CrossRefPubMed

41.

G. Sesmilo, E. Resmini, I. Bernabeu, J. Aller, A. Soto, M. Mora, A. Pico, C. Fajardo, E. Torres, C. Alvarez-Escola, R. Garcia, C. Blanco, R. Camara, S. Gaztambide, I. Salinas, C.D. Pozo, I. Castells, C. Villabona, B. Biagetti, S.M. Webb, Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish study. Clin. Endocrinol. 81(6), 883–890 (2014). https://doi.org/10.1111/cen.12440 CrossRef

42.

I. Bernabeu, A. Pico, E. Venegas, J. Aller, C. Alvarez-Escola, J.A. Garcia-Arnes, M. Marazuela, P. Jonsson, N. Mir, M. Garcia Vargas, A.G. Spanish, Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY. Pituitary 19(2), 127–137 (2016). https://doi.org/10.1007/s11102-015-0691-0 CrossRefPubMed

43.

M. Puig-Domingo, A. Soto, E. Venegas, R. Vilchez, C. Blanco, F. Cordido, T. Lucas, M. Marazuela, R. Casany, G. Cuatrecasas, C. Fajardo, M.A. Galvez, S. Maraver, T. Martin, E. Romero, M. Paja, A. Pico, I. Bernabeu, E. Resmini; ACROCOMB study group, Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: the ACROCOMB study. Endocrinol. Nutr. 63(8), 397–408 (2016). https://doi.org/10.1016/j.endonu.2016.05.010 CrossRefPubMed

44.

A.M. Ramos-Levi, I. Bernabeu, C. Alvarez-Escola, J. Aller, T. Lucas, P. de Miguel, L. Rodriguez-Canete, M.A. Sampedro-Nunez, I. Halperin, M. Puig-Domingo, M. Marazuela, Long-term treatment with pegvisomant for acromegaly: a 10-year experience. Clin. Endocrinol. 84(4), 540–550 (2016). https://doi.org/10.1111/cen.12993 CrossRef

45.

E. Kuhn, L. Maione, A. Bouchachi, M. Roziere, S. Salenave, S. Brailly-Tabard, J. Young, P. Kamenicky, P. Assayag, P. Chanson, Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study. Eur. J. Endocrinol. 173(5), 693–702 (2015). https://doi.org/10.1530/EJE-15-0500 CrossRefPubMedPubMedCentral

46.

P. Chanson, T. Brue, B. Delemer, P. Caron, F. Borson-Chazot, H. Zouater, Medecins de l’Etude ACROSTUDY. Pegvisomant treatment in patients with acromegaly in clinical practice: the French ACROSTUDY. Ann. Endocrinol. 76(6), 664–670 (2015). https://doi.org/10.1016/j.ando.2015.10.003 CrossRef

47.

N.G. Basavilbaso, M. Guitelman, A. Nagelberg, G. Stalldecker, A. Carabelli, O. Bruno, K. Danilowitz, M. Manavela, S. Mallea Gil, C. Ballarino, R. Guelman, D. Katz, S. Fidalgo, R. Leal, H. Fideleff, M. Servidio, D. Bruera, F. Librandi, A. Chervin, M. Vitale, A. Basso, Experience from the Argentine Pegvisomant Observational Study: preliminary data. Front. Horm. Res. 38, 42–49 (2010). https://doi.org/10.1159/000318493 CrossRef

48.

M. Madsen, S. Fisker, U. Feldt-Rasmussen, M. Andreassen, L.O. Kristensen, H. Orskov, J.O. Jorgensen, Circulating levels of pegvisomant and endogenous growth hormone during prolonged pegvisomant therapy in patients with acromegaly. Clin. Endocrinol. 80(1), 92–100 (2014). https://doi.org/10.1111/cen.12239 CrossRef

49.

L. Kasuki, E.O. Machado, L.L. Ogino, M.C. Coelho, C.M. Silva, L.E. Wildemberg, C.H. Lima, M.R. Gadelha, Experience with pegvisomant treatment in acromegaly in a single Brazilian tertiary reference center: efficacy, safety and predictors of response. Arch. Endocrinol. Metab. 60(5), 479–485 (2016). https://doi.org/10.1590/2359-3997000000210 CrossRefPubMed

50.

O. Haliloglu, E. Kuruoglu, H.M. Ozkaya, F.E. Keskin, O. Gunaldi, B. Oz, N. Gazioglu, P. Kadioglu, N. Tanriover, Multidisciplinary approach for acromegaly: a single tertiary center’s experience. World Neurosurg. 88, 270–276 (2016). https://doi.org/10.1016/j.wneu.2015.12.092 CrossRefPubMed

51.

O. Karapanou, M. Tzanela, M. Christoforaki, L. Papastathopoulou, P. Moutsatsou, E. Botoula, S. Tsagarakis, Therapeutic trends and outcome of acromegaly: a single-center experience over a 40-year period. Hormones 15(3), 368–376 (2016). https://doi.org/10.14310/horm.2002.1680 CrossRefPubMed

52.

L. Ferreri, R.S. Auriemma, L.F.S. Grasso, R. Pivonello, A. Colao , Efficacy and tolerability of treatment with pegvisomant in acromegaly: an overview of literature. Expert Opinion on Orphan. Drugs 3(1), 12 (2015). https://doi.org/10.1517/21678707.2014.970171 CrossRef

53.

A. Giustina, G. Arnaldi, F. Bogazzi, S. Cannavo, A. Colao, L. De Marinis, E. De Menis, E. Degli Uberti, F. Giorgino, S. Grottoli, A.G. Lania, P. Maffei, R. Pivonello, E. Ghigo, Pegvisomant in acromegaly: an update. J. Endocrinol. Invest. 40(6), 577–589 (2017). https://doi.org/10.1007/s40618-017-0614-1 CrossRefPubMedPubMedCentral

54.

A.N. Paisley, P. Trainer, W. Drake, Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly. Expert Opin. Biol. Ther. 4(3), 421–425 (2004). https://doi.org/10.1517/14712598.4.3.421 CrossRefPubMed

55.

E. Ghigo, B.M. Biller, A. Colao, I.A. Kourides, N. Rajicic, R.K. Hutson, L. De Marinis, A. Klibanski, Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naive to radiation and medical therapy. J. Endocrinol. Invest. 32(11), 924–933 (2009). https://doi.org/10.3275/672310.1007/BF03345774 CrossRefPubMed

56.

A. Colao, R.S. Auriemma, R. Pivonello, The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly. Pituitary 19(2), 210–221 (2016). https://doi.org/10.1007/s11102-015-0677-y CrossRefPubMed

57.

G. Mazziotti, A. Giustina, Effects of lanreotide SR and autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary 13(1), 60–67 (2010). https://doi.org/10.1007/s11102-009-0169-z CrossRefPubMed

58.

M.J. Rousseau, J.C. Evans, Key statistical assumptions and methods in one arm meta-analyses with binary endpoints and low event rates, including a real-life example in the area of endoscopic colonic stenting. Cogent Med 4(1), 1334318 (2017). https://doi.org/10.1080/2331205X.2017.1334318 CrossRef

Title: Effectiveness and safety of pegvisomant: a systematic review and meta-analysis of observational longitudinal studies
Authors: Letícia P. Leonart
Fernanda S. Tonin
Vinicius L. Ferreira
Fernando Fernandez-Llimos
Roberto Pontarolo
Publication date: 01-01-2019
Publisher: Springer US
Published in: Endocrine / Issue 1/2019
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-018-1729-7

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Effectiveness and safety of pegvisomant: a systematic review and meta-analysis of observational longitudinal studies

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2019

Analysis of risk factors of metabolic syndrome using a structural equation model: a cohort study

18F-FDG PET reveals an adrenocortical carcinoma in a bilateral adrenal multinodular disease

Clinical and prognostic role of detection timing of distant metastases in patients with differentiated thyroid cancer

Adult individuals with congenital, untreated, severe isolated growth hormone deficiency have satisfactory muscular function

Signs and symptoms of acromegaly at diagnosis: the physician’s and the patient’s perspectives in the ACRO-POLIS study

Absence of EIF1AX, PPM1D, and CHEK2 mutations reported in Thyroid Cancer Genome Atlas (TCGA) in a large series of thyroid cancer

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page